These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8555597)

  • 1. Oxidative damage to RBC membranes and pentose phosphate shunt activity in hemodialysis patients after suspension of erythropoietin treatment.
    Taccone-Galluci M; Lubrano R; Trapasso E; Clerico A; Latorre P; Meloni C; Morosetti M; Castello MA; Casciani CU
    ASAIO J; 1994; 40(3):M663-6. PubMed ID: 8555597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; van Kuijk FJ; Ehrich JH; Siems WG
    Nephrol Dial Transplant; 1998 Oct; 13(10):2583-7. PubMed ID: 9794564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disappearance of oxidative damage to red blood cell membranes in uremic patients following renal transplant.
    Taccone-Gallucci M; Lubrano R; Belli A; Meloni C; Morosetti M; Meschini L; Elli M; Boffo V; Pisani F; Giardini O
    ASAIO Trans; 1989; 35(3):533-5. PubMed ID: 2597526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of GSH has no influence on the RBC membrane: oxidative damage to patients on hemodialysis.
    Taccone-Gallucci M; Lubrano R; Clerico A; Meloni C; Morosetti M; Meschini L; Elli M; Trapasso E; Castello MA; Casciani CU
    ASAIO J; 1992; 38(4):855-7. PubMed ID: 1450486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E-bonded cellulose membrane, lipoperoxidation, and anemia in hemodialysis patients.
    Triolo L; Malaguti M; Ansali F; Comunian MC; Arcangeloni O; Coppolino F; Marrocco F; Sicoli R; Biagini M
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):185-91. PubMed ID: 12751839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.
    Herrera J; Nava M; Romero F; Rodríguez-Iturbe B
    Am J Kidney Dis; 2001 Apr; 37(4):750-7. PubMed ID: 11273875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentose-phosphate shunt activity and red blood cell malonyldialdehyde levels in haemodialysis and in CAPD patients.
    Taccone-Gallucci M; Giardini O; Lubrano R; Mazzarella V; Bandino D; Meloni C; Elli M; Citti F; Cozzari M; Buoncristiani U
    Life Support Syst; 1985; 3 Suppl 1():121-4. PubMed ID: 3870550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication.
    Zachée P; Ferrant A; Daelemans R; Goossens W; Boogaerts MA; Lins RL
    Nephron; 1995; 71(3):343-9. PubMed ID: 8569984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron.
    Delmas-Beauvieux MC; Combe C; Peuchant E; Carbonneau MA; Dubourg L; de Précigout V; Aparicio M; Clerc M
    Nephron; 1995; 69(4):404-10. PubMed ID: 7777104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of red blood cell membrane lipid peroxidation in haemodialysis patients.
    Giardini O; Taccone-Gallucci M; Lubrano R; Ricciardi-Tenore G; Bandino D; Silvi I; Ruberto U; Casciani CU
    Nephron; 1984; 36(4):235-7. PubMed ID: 6709116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
    Lezaic V; Djukanovic L; Pavlovic-Kentera V
    Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia and carnitine supplementation in hemodialyzed patients.
    Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
    Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia.
    Hirayama A; Nagase S; Gotoh M; Ueda A; Ishizu T; Yoh K; Aoyagi K; Terao J; Koyama A
    Free Radic Res; 2002 Nov; 36(11):1155-61. PubMed ID: 12592667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.